Skip to content

The effect of Ginkgo biloba pill and inhalation aromatherapy on sexual function in postmenopausal women

The effect of Ginkgo biloba pill and inhalation aromatherapy on sexual function in postmenopausal women: A randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201405108170N7
Enrollment
180
Registered
2014-06-17
Start date
2014-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sexual function during postmenopausal. Unspecified sexual dysfunction, not caused by organic disorder or disease

Interventions

Intervention 1: the first intervention group aromas solution (containing plant extracts Lavndvr, geranium, fennel and rose) and placebo Jynkubyluba 3 times daily for 6 weeks with 3-2 drops of aromas
Treatment - Drugs
the first intervention group aromas solution (containing plant extracts Lavndvr, geranium, fennel and rose) and placebo Jynkubyluba 3 times daily for 6 weeks with 3-2 drops of aromas on the skin an
the secound intervention group tablets containing herbal Jynkubyluba and placebo aromas . 3 times daily for 6 weeks with 3-2 drops of aromas on the skin and 40mg tablets Jynkubyluba 3 times daily .
third, 2 placebo 3 times daily for 6 weeks with 3-2 drops of aromas on the skin and 40mg tablets Jynkubyluba3 times .

Sponsors

Vice Chancellor for research of Faculty of Nursing and Midwifery, Tabriz Univercity of Medical Scien
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: ability of writing in Persian language? age range of 45- 55 years; Being married and living with her husband; Lack of chronic disease; No severe emotional stress in past six months; Natural menopause Exclusion criteria: No willingness to participate; occurrence of drug side effects and allergy to drugs during the study; occurrence of severe emotional stress such as death of close family; occurrence of psychological complications or severe disease during the study; Living away from husband; hysterectomy,ovarectomy , Cystocele, mastectomy, use of tobacco and alcohol, or herbal drugs, impaired sense of smell, according to one's own and other nasal problems (fractures, SD, rhinitis), gastrointestinal disturbances such as nausea, vomiting, stomach - ache, abdominal cramps, absence of any abnormal vaginal bleeding; Not currently taking drugs affecting on sexual response (anti-hypertension, Thiazide diuretics, anti-depression, anti-histamines, Barbiturates, narcotics, diazepam,amphetamines,cocaine) & no HRT

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Sexual function. Timepoint: Before intervention,6 weeks after intervention. Method of measurement: Female Sexual Function Index (FSFI) that will be self-administered and will be put into a sealed box.

Secondary

MeasureTime frame
Adverse events. Timepoint: During the intervention. Method of measurement: Checklist.;The degree of satisfaction. Timepoint: during intervention and aftre intervention. Method of measurement: Check list.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMalakouti Jamileh

Tabriz University of Medical Sciences

malakoutij@tbzmed.ac.ir+98 41 1479 6770

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026